CRITICAL ILLNESS-RELATED CORTICOSTEROID INSUFFICIENCY

SUMMARY
Critically ill patients are at risk for the development of Critical Illness-Related Corticosteroid Insufficiency (CIRCI). This has previously been known as “Relative Adrenal Insufficiency (RAI)” and “Adrenal Insufficiency in Critical Illness (AICI).” This may present as hypotension, unresponsiveness to catecholamine infusions, and/or ventilator dependence. Such patients may benefit from administration of exogenous steroids to restore their hemodynamic stability. Critically ill patients who were on chronic steroid therapy prior to injury or illness may also require steroid supplementation.

RECOMMENDATIONS

- **Level 1**
  - Consider CIRCI and obtain a serum cortisol level in any critically ill patient who demonstrates hypotension, refractory shock, hypoglycemia, persistent systemic inflammation, and/or marked eosinophilia.

- **Level 2**
  - When CIRCI is present and clinically indicated, initiate steroid replacement using hydrocortisone 100 mg IV Q 8 hours.
  - Testing should not delay treatment in cases in which CIRCI is strongly suspected in the unstable patient.
  - CIRCI is strongly suspected with a random serum cortisol of <10 mcg/dL and can be relatively ruled out with a random serum cortisol >34 mcg/dL.
  - Consider stimulation testing with 250 mcg ACTH with values between 10-34 mcg/dL in patients who can tolerate delayed treatment (see below for stimulation testing instructions).
    - CIRCI should be suspected in critically ill patients with a delta serum cortisol of <9 mcg/dL.

- **Level 3**
  - For patients on steroid therapy for ≤7 days, steroid weaning is not necessary.
  - For patients on steroid therapy for >7 days, wean steroid replacement by 25-50% per day as tolerated by the patient’s response

INTRODUCTION
Cortisol is vitally important to the maintenance of vascular tone, endothelial integrity, vascular permeability, and total body water distribution. It also potentiates the vasoconstrictor actions of both endogenous and exogenous catecholamines. Appropriate activation of the hypothalamic-pituitary-adrenal (HPA) axis in the critically ill patient is essential to stress adaptation and maintenance of

EVIDENCE DEFINITIONS

- **Class I:** Prospective randomized controlled trial.
- **Class II:** Prospective clinical study or retrospective analysis of reliable data. Includes observational, cohort, prevalence, or case control studies.
- **Class III:** Retrospective study. Includes database or registry reviews, large series of case reports, expert opinion.
- **Technology assessment:** A technology study which does not lend itself to classification in the above-mentioned format. Devices are evaluated in terms of their accuracy, reliability, therapeutic potential, or cost effectiveness.

LEVEL OF RECOMMENDATION DEFINITIONS

- **Level 1:** Convincingly justifiable based on available scientific information alone. Usually based on Class I data or strong Class II evidence if randomized testing is inappropriate. Conversely, low quality or contradictory Class I data may be insufficient to support a Level I recommendation.
- **Level 2:** Reasonably justifiable based on available scientific evidence and strongly supported by expert opinion. Usually supported by Class II data or a preponderance of Class III evidence.
- **Level 3:** Supported by available data, but scientific evidence is lacking. Generally supported by Class III data. Useful for educational purposes and in guiding future clinical research.
homeostasis. Common causes of adrenal insufficiency in the critical care setting include infection, systemic inflammation, previous glucocorticoid use, and sepsis (1).

While the incidence of CIRCI in the critically ill has been under appreciated, the detrimental impact of such dysfunction is well recognized. CIRCI may be characterized by any of the following findings with delayed weaning from mechanical ventilation and hypotension refractory to fluids and vasopressors being most common (1-3):

- Hypotension
- Unresponsiveness to catecholamine infusions
- Ventilator dependence
- Abdominal or flank pain
- High fever with negative cultures and unresponsive to antibiotic therapy
- Unexplained mental changes (i.e., apathy or depression)
- Electrolyte abnormalities (hypoglycemia, hyponatremia, hyperkalemia)
- Neutropenia, eosinophilia

Diagnostic criteria for CIRCI in the critically ill are not well established, but evidence suggests that modifications from standard testing are warranted. Random serum cortisol levels, free cortisol, and delta cortisol (change in baseline cortisol at 60 minutes after ACTH stimulation using 250 mcg cosyntropin) are all ways to evaluate for CIRCI. Free cortisol level testing is not available at most hospitals. A majority of experts will agree that a random serum cortisol <10 mcg/dL is low and >34 mcg/dL is high. Controversy of how to interpret levels between 10 and 34 mcg/dL exists (4, 5).

**HYPOTHALAMIC-PITUITARY-ADRENAL AXIS TESTING**

If CIRCI is suspected in an adequately stressed ICU patient, obtain a random serum cortisol level. There is no need to wait until morning since diurnal variation is lost in the critically ill. A random level of < 10 mcg/dL in the presence of hemodynamic instability is diagnostic of CIRCI and glucocorticoid replacement therapy should be initiated. In patients with indeterminate random cortisol levels (10-34 mcg/dL), a delta cortisol level is diagnostic. However, the adrenocorticotropic hormone stimulation test should not be used to identify those patients with septic shock who should receive glucocorticoids (5,6). In order to stimulation test for CIRCI when the initial cortisol level is indeterminate (random between 10-34 mcg/dL), a second cortisol level is drawn 60 minutes after the administration of 250 mcg of intravenous cosyntropin. If the patient can clinically tolerated further testing before treatment this may be performed. The T60 cortisol minus the T0 cortisol results in the delta value. Cortisol levels > 34 mcg/dL are sufficient to confirm adequate adrenal function (7,8).

**GLUCOCORTICOID REPLACEMENT THERAPY**

If CIRCI is detected, patients should be immediately started on corticosteroid replacement therapy. Dexamethasone is no longer recommended secondary to its prolonged suppression of the HPA axis and offers no benefit in the absence of an ACTH stimulation test (9). Glucocorticoid administration during stress should be based upon the magnitude of the stress and the known glucocorticoid production rate associated with it (10).

Mineralocorticoid replacement is seldom necessary in the acute setting, but electrolyte and fluid status should be followed closely. Whereas patients who are found to be adrenally insufficient will require full adrenal replacement therapy, patients who have been on steroid therapy chronically do not necessarily need full replacement dosages. Further, studies have demonstrated that steroid replacement therapy does not need to be continued for weeks to months as has historically been performed. Suggested dosages and durations of therapy for steroid replacement are listed in Tables 1 and 2.

**STEROID WEANING**

Once the patient is stable and no longer in need of vasopressor therapy, steroids may be discontinued or tapered. Suppression of the HPA-axis can occur with the long-term administration of systemic
corticosteroids. This results in a decrease in endogenous ACTH secretion. Suppression increases with increasing dose and duration of therapy. Less potent corticosteroids such as hydrocortisone are not as likely to cause suppression as more potent agents such as methylprednisolone or dexamethasone. Steroid therapy for less than 7 days is unlikely to cause clinically significant HPA-axis suppression (11). Trials have successfully treated patients for 7-10 days with no gradual dosage decrease and no increase in adverse events (7,12). Tapering therapy results in an increased duration of treatment that may increase the incidence of adverse events (8). For patients on steroid therapy for less than or equal to 7 days, steroid weaning is not necessary. For patients on steroid therapy for greater than 7 days, the dose should be decreased by 25-50% per day as tolerated by the patient's hemodynamic status.

LITERATURE REVIEW

Karir et al. examined the practice variability in the assessment and treatment of CIRCI at their tertiary-care academic institution. They found the treatment and evaluation to be inconsistent. Many patients with vasopressor dependent septic shock did not receive either treatment or evaluation for CIRCI, and patients who do not meet the current criteria were being evaluated and/or treated for CIRCI (13).

Bury et al. examined the incidence of CIRCI in patients with septic shock using a 1 mcg corticotropin (ACTH) test and to describe their clinical outcomes. They retrospectively identified 219 consecutive patients with septic shock assessed for CIRCI with 1 mcg ACTH test. Standardized testing involved plasma cortisol measurements at baseline (T0) and at 30 min (T30) and 60 min (T60) after ACTH administration. The maximal increase in cortisol (delta max) was calculated as the difference between T0 and the highest cortisol value at T30 or T60. CIRCI was defined as a delta max <9 mcg/dL after ACTH administration. Patients with CIRCI had similar ICU mortality whether or not they received corticosteroids (46% vs. 25% P=0.1666. The highest mortality rates were observed in patients with high baseline cortisol and in those who failed to respond appropriately to ACTH. The administration of corticosteroids was not associated with a reduction in mortality (14).

Molenaar et al. set out to study the value of free versus total cortisol levels in assessing relative adrenal insufficiency during critical illness-related corticosteroid insufficiency. This single center prospective study included 49 septic and 69 non-septic patients with treatment-insensitive hypotension in whom an adrenocorticotropic hormone (ACTH) test (250 mcg) was performed. They found that subnormal increments in total cortisol upon ACTH suffice in assessing relative adrenal insufficiency, particularly in sepsis (15).

Marik et al. published a consensus statement that coined the term critical illness-related corticosteroid insufficiency (CIRCI). They defined adrenal insufficiency in critically ill patients as a delta total serum cortisol of <9 mcg/dL after adrenocorticotropic hormone (250 mcg/dL) administration or a random total cortisol of <10 mcg/dL. They also stated that the stimulation test should not be used to identify those patients with septic shock or acute respiratory distress syndrome who should receive glucocorticoids (16).

Yang et al. investigated the prevalence, time course, and effect of CIRCI on the outcome of critically ill patients with multiple injuries. They prospectively found that the CIRCI patients with a delta cortisol of less than 9 mcg/dL had a significantly higher 28-day mortality (39.3%) compared with those with a baseline cortisol level of less than 10 mcg/dL (10%) and non-CIRCI patients (6.3%) (17).

Schroeder et al. prospectively examined the HPA axis in surgical intensive care patients with severe sepsis. An IV bolus of human CRH was administered to test response to cortisol in survivors and nonsurvivors. Baseline cortisol levels in those with severe sepsis were lower in nonsurvivors (10.3 mcg/dL) than in survivors (16.8 mcg/dL). Nonsurvivors were also found to have an impaired response to CRH stimulation, which may reflect endocrine dysfunction in patients with severe sepsis (Class II) (18).

Cooper et al. suggested a new definition for AlCl consisting of a baseline cortisol of < 15 mcg/dL. They postulated that AlCI was highly unlikely if the random serum cortisol was > 34 mcg/dL and likely if < 15 mcg/dL. For cortisol levels falling between these limits, further evaluation using 250 mcg of ACTH was recommended (19).
The use of hydrocortisone and fludrocortisone in patients with septic shock and adrenal insufficiency was examined by Annane et al. Study patients were defined as having septic shock with a systolic blood pressure ≤ 90 mm Hg for more than one hour despite fluid and vasopressor therapy. The investigators found that seven days of treatment with low dose steroids significantly reduced the risk of death in nonresponders to the corticotropin test, as well as in the overall treatment population, which included corticotropin responders. There was no significant increase in adverse events in the steroid group (Class I). (20)

The CORTICUS trial, performed by Sprung et al., compared hydrocortisone 50 mg IV every 6 hours versus placebo in patients with septic shock who did (50.9%) and did not (46.7%) have a response to corticotropin (9). A response to corticotropin was defined as in increase of > 9 mcg/dL after administration of 250 mcg Cosyntropin®. After day five, hydrocortisone was gradually tapered until discontinuation on day 12. At 28 days, there was found to be no significant difference in mortality between groups. There were a similar proportion of patients with shock reversal, but a significantly shorter time to reversal in the hydrocortisone group in all patient populations. The use of the ACTH test did not predict faster shock resolution. A post-hoc analysis showed an increased rate of death in patients receiving etomidate (20.3% vs 18.1%). An increased incidence of super-infections (new episodes of sepsis or septic shock within 48 hours of drug initiation) was seen in the hydrocortisone group, as well as increased rates of hyperglycemia and hypernatremia. Due to the weaning schedule over 7 days, patients were exposed to hydrocortisone for a longer duration than seen in previous trials, which may have contributed to the increased incidence of adverse events (Class I) (21).

According to a retrospective study in critically injured patients by Cotton et al., exposure to etomidate may increase the risk of adrenal insufficiency (11). Etomidate inhibits 11β-hydroxylase which results in blockage of adrenal cortisol production for 4-8 hours in the general population, and up to 24 hours in the ICU or elderly population. In light of this trial and results of the CORTICUS trial post-hoc analysis, patients receiving etomidate for rapid sequence intubation may be at greater risk of adrenal insufficiency (Class III) (22).

REFERENCES


Table 1. Recommendations for Steroid Replacement Therapy (12)

<table>
<thead>
<tr>
<th>Indications</th>
<th>Total Daily Dosage</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minor Surgical Stress</td>
<td>Hydrocortisone 10 mg IV q 8 hours</td>
<td>If procedure is uncomplicated, patient may resume preoperative steroid dose on POD # 1</td>
</tr>
<tr>
<td>• Inguinal herniorrhaphy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Breast biopsy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Laparoscopic cholecystectomy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate Surgical Stress</td>
<td>Hydrocortisone 25 mg IV q 8 hours</td>
<td>If procedure is uncomplicated, patient may resume preoperative steroid dose on POD # 2</td>
</tr>
<tr>
<td>• Open cholecystectomy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Fem-pop bypass</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Total joint replacement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Abdominal hysterectomy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major Surgical Stress</td>
<td>Hydrocortisone 100 mg IV q 8 hours</td>
<td>If procedure is uncomplicated, patient may resume preoperative steroid dose on POD # 3</td>
</tr>
<tr>
<td>• Pancreaticoduodenectomy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Major trauma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Sepsis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• ARDS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Corticosteroid Equivalencies

<table>
<thead>
<tr>
<th>Drug</th>
<th>Equivalent Dose (mg)</th>
<th>Route of Administration</th>
<th>Relative Anti-inflammtory Potency</th>
<th>Relative Mineralocorticoid Potency</th>
<th>Half-life (hrs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betamethasone</td>
<td>0.6-0.75</td>
<td>IM,IV,PO</td>
<td>20-30</td>
<td>0</td>
<td>36-54</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>0.75</td>
<td>IM,IV,PO</td>
<td>25-30</td>
<td>0</td>
<td>36-54</td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>20</td>
<td>IM,IV,PO</td>
<td>1</td>
<td>2</td>
<td>8-12</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>4</td>
<td>IM,IV,PO</td>
<td>5</td>
<td>0</td>
<td>18-36</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>5</td>
<td>PO</td>
<td>4</td>
<td>1</td>
<td>18-36</td>
</tr>
<tr>
<td>Prednisone</td>
<td>5</td>
<td>PO</td>
<td>4</td>
<td>1</td>
<td>18-36</td>
</tr>
</tbody>
</table>